AB 432 mandates that most California health care service plans and health insurance policies covering outpatient prescription drugs include evaluation and treatment options for perimenopause and menopause — with minimum formulary requirements across drug types and administration routes and a ban on utilization management for FDA‑approved treatments. The law also requires plans and insurers to distribute current hormone‑therapy clinical guidance to contracted primary care providers.
Separately, the bill creates a temporary continuing medical education incentive: qualifying MDs and DOs who take coursework in perimenopause, menopause, and postmenopausal care receive two hours of license credit for each hour of coursework (capped) during a defined window. The combination of coverage mandates and education incentives aims to expand access and increase clinician familiarity but raises operational, cost, and regulatory questions for payers, PBMs, and provider organizations.
At a Glance
What It Does
Requires most commercial health plans and insurers that cover outpatient prescriptions to include evaluation and treatment options for menopause symptoms, specifying minimum drugs by formulation and administration route and forbidding utilization management for FDA‑approved treatments. Provides a temporary accelerated CME credit (2-for-1 up to a cap) for certain physicians who complete menopause‑focused coursework.
Who It Affects
Commercial health care service plans regulated under Knox‑Keene, health insurers regulated by the Department of Insurance, pharmacy benefit managers and formulary committees, primary care providers and listed specialists (OB‑GYN, cardiology, endocrinology, neurology, psychiatry, family medicine, internal medicine), and perimenopausal/menopausal patients including people whose gender expression or identity differs from their sex assigned at birth.
Why It Matters
The bill establishes a statutory minimum for what insurers must cover for menopause care and limits utilization controls for FDA‑approved options, which can reshape formularies and utilization management programs. The CME incentive targets clinician competence where patient demand is high — a regulatory nudge that could change prescribing behavior and referral patterns.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 432 inserts parallel coverage rules into California's Health and Safety Code (for Knox‑Keene plans) and Insurance Code (for regulated health insurers). For contracts and policies issued, amended, or renewed on or after January 1, 2026, carriers that cover outpatient prescription drugs must include evaluation and treatment options for perimenopause and menopause.
The statute sets a floor: insurers must carry at least one outpatient prescription in each listed formulation and method of administration for systemic hormone therapy, nonhormonal medications targeted to menopause symptoms, treatments for genitourinary syndrome of menopause, and at least one drug from each class approved for osteoporosis. For FDA‑approved treatments, plans cannot impose utilization management, and treating clinicians retain authority to adjust dosing consistent with clinical recommendations.
The coverage obligation carves out a few limits. It does not apply to specialized policies or contracts, and it excludes Medi‑Cal managed care contracts under state Medi‑Cal law.
The bill also mandates that plans and insurers annually circulate current clinical care recommendations for hormone therapy (for example, from the Menopause Society) to contracted primary care providers and encourage their review. The statute defines 'formulation' and 'method of administration' in a way that forces plans to think about tablets, transdermals, topicals, rings, injections, and more — not just a single molecule on a formulary list.On the professional education side, AB 432 adds two related provisions to the Business and Professions Code.
It creates a temporary credit bonus for qualifying physicians and surgeons: between July 1, 2026, and July 1, 2032, an eligible MD who completes approved menopause coursework receives two hours of continuing medical education (CME) credit for every hour completed, up to a total of eight course hours toward state CME requirements. The bill imposes the same credit structure on osteopathic physicians.
The law also removes the prior explicit instruction in the Medical Practice Act that the Medical Board consider including a course specifically on menopausal mental or physical health in its list of topics to consider — a curious contrast with the new CME incentive structure.Several operational consequences follow. Plan formularies and PBM rules will need reconciliation with the minimum‑formulation requirement and the prohibition on utilization management for FDA‑approved options; pharmacy operations must be ready to dispense multiple formulations and routes; and primary care practices will receive annual clinical guidance meant to standardize hormone‑therapy practice.
Enforcement paths differ: coverage obligations live in the Health and Safety Code and Insurance Code frameworks, while a willful Knox‑Keene violation carries potential criminal exposure. The bill does not attempt to change federal preemption for self‑funded ERISA plans, so its reach will be limited to state‑regulated coverage.
The Five Things You Need to Know
Coverage requirement: For contracts or policies issued, amended, or renewed on or after Jan 1, 2026, carriers that cover outpatient prescription drugs must include evaluation and treatment options for perimenopause and menopause (specialized policies excluded).
Formulation and method floor: Plans must carry at least one outpatient drug in each formulation and associated method of administration for systemic hormone therapy, nonhormonal symptom treatments, genitourinary syndrome of menopause therapies, and at least one drug from each osteoporosis drug class.
Utilization management and dosing: Treatments approved by the FDA must be covered without utilization management, and treating providers retain authority to adjust doses consistent with clinical care recommendations.
CME incentive: From July 1, 2026, until July 1, 2032, qualifying physicians (ABMS‑certified in specified specialties whose patient panels are ≥25% adult women under 65) receive two hours of license credit for each hour of approved menopause coursework, up to eight course hours.
Scope and exclusions: The mandate does not apply to Medi‑Cal managed care contracts and excludes specialized health plans/policies; annual clinical guidance must be distributed to contracted primary care providers (e.g.
Menopause Society recommendations).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Temporary enhanced CME credit for selected MDs
Creates a targeted CME credit incentive for 'qualifying physician and surgeon' licensees: specified ABMS‑certified specialties whose practices include at least 25% adult women under age 65. The mechanics double credit (2 hours of credit per hour of coursework) up to a maximum of eight course hours toward existing CME requirements and applies only from July 1, 2026 through July 1, 2032. Practically, licensing boards and accredited CME providers must track eligible participants and ensure course content meets state criteria for perimenopause/menopause/postmenopausal care.
Removes prior menopause consideration in Medical Board list
Amends the Medical Practice Act's continuing education consideration list but omits the prior explicit direction that the board consider including a course in menopausal mental or physical health. The change leaves the board free to decide whether to add menopause as a named topic but pairs oddly with the new temporary CME credit created elsewhere; enforcement and curriculum prioritization now rest with the board's general rulemaking rather than an explicit statutory command.
Parallel CME credit rule for DOs
Mirrors the MD provision for osteopathic physicians and surgeons, granting the same two‑for‑one credit for approved menopause coursework up to the same cap and within the same July 2026–July 2032 window. Osteopathic boards and accredited CME sponsors must implement equivalent tracking and validation procedures for DO licensees.
Knox‑Keene plans: mandated prescription coverage and provider guidance
Imposes a minimum prescription coverage requirement on health care service plans that cover outpatient drugs (excluding specialized contracts and Medi‑Cal managed care). The statute specifies required categories and formulations, prohibits utilization management for FDA‑approved therapies, and obliges plans to send annual clinical care recommendations to contracted primary care providers. Because Knox‑Keene enforcement can include administrative and criminal penalties for willful violations, plan compliance teams and regulators will have enforcement tools beyond civil remedies.
Parallel mandate for regulated health insurers
Adopts the same coverage floor and provider‑guidance requirements for health insurers under the Insurance Code, with identical definitions for formulation and administration routes. Department of Insurance oversight, rather than the Department of Managed Health Care, will govern complaints and enforcement for insurers, which may affect how carriers adjust rates, reserves, and formulary design.
No state reimbursement required — criminality exception
Declares that the bill imposes no reimbursable state‑mandated costs on local agencies under Article XIII B because any local costs arise from creating, eliminating, or redefining crimes or infractions. This signals the drafters' position that enforcement-related local expenses (e.g., prosecutorial activity tied to willful Knox‑Keene violations) do not trigger state reimbursement obligations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Perimenopausal and menopausal patients — gain statutory access to a baseline set of outpatient pharmacologic options across multiple formulations and administration routes, reducing formulary gaps that previously forced switches or out‑of‑pocket purchases.
- Primary care providers — receive annual, standardized clinical guidance (for example, Menopause Society recommendations) and explicit authority to adjust doses, which supports point‑of‑care decision making and may reduce administrative friction when prescribing.
- Clinicians in qualifying specialties (OB‑GYN, family medicine, internal medicine, cardiology, endocrinology, neurology, psychiatry) — benefit from a temporary CME credit incentive that lowers the effective cost of obtaining menopause‑focused education and may accelerate competency.
- Manufacturers and pharmacies offering required formulations — stand to see increased demand for covered formulations and routes, particularly companies producing transdermal, topical, and vaginal preparations.
- Advocacy groups focused on women's and transgender health — gain a statutory ally for improved access and nondiscriminatory coverage for gender diverse people experiencing menopause.
Who Bears the Cost
- State‑regulated health plans and insurers — must expand formularies and adjust utilization management and prior‑authorization systems, which can increase drug spend and administrative overhead.
- Pharmacy benefit managers and formulary committees — face new constraints when designing step therapy and utilization controls for FDA‑approved menopause treatments, potentially reducing negotiation leverage for lower‑cost alternatives.
- Employers with fully insured plans — may see premium increases as carriers price in broader coverage obligations; by contrast, self‑funded ERISA employers may be unaffected, creating coverage disparities.
- Regulatory agencies and plan compliance teams — need to update guidance, complaint processes, and monitoring for adherence to the new coverage floor and the annual guidance distribution requirement.
- Medical boards and CME providers — must develop certification and recordkeeping mechanisms for the temporary two‑for‑one credit scheme and reconcile it with existing continuing education frameworks.
Key Issues
The Core Tension
The central dilemma is access versus clinical and cost flexibility: the bill increases patient access by mandating a baseline set of covered menopause therapies and restricting utilization controls, while simultaneously constraining payers' ability to manage utilization and costs and leaving open difficult implementation questions (formulary choices, clinical exceptions, and uneven reach because of ERISA and Medi‑Cal carveouts).
The bill erects a clear coverage floor but leaves substantial discretion and unanswered operational questions. 'At least one drug in each formulation and method' forces plans to cover a matrix of products that can include high‑cost or low‑volume formulations; carriers will need to decide whether to select lower‑cost representatives in each category or include multiple branded and generic options, with implications for negotiations with manufacturers and PBMs. The ban on utilization management for FDA‑approved therapies narrows one of the principal cost‑control levers for payers; plans may shift to other tactics (narrower networks, step edits at the physician level, or tighter quantity limits) unless regulators strictly define 'utilization management' and its permissible alternatives.
The bill's reach is uneven. It applies to state‑regulated plans and policies but does not change coverage rules for Medi‑Cal managed care or necessarily affect self‑insured ERISA plans, creating a patchwork of coverage across populations.
The temporary CME credit is targeted but administratively awkward: verifying a clinician’s '25 percent or more' adult‑women patient mix and ensuring coursework meets the statute's topical requirements will require operational guidance from licensing boards. Finally, criminal exposure for willful Knox‑Keene violations is a blunt enforcement tool; its presence raises the stakes for plan compliance but may chill carriers or prompt costly defensive policies rather than thoughtful clinical integration.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.